In addition, there is an urgent need for alternative therapies for IBD patients, which do not respond to current first-line treatments.45 To help meet this clinical gap, we propose the possibility of screening specifically for patients for NE activity and treating this subset with NE inhibitors. This evidence concerns the gene ELANE and inflammatory bowel disease.